MedTrace Logo

Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma

NCT05014100 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 55

Last updated 2021-08-27

No results posted yet for this study

Summary

Obrutinib is a highly selective BTKi and has shown efficacy in CLL/MCL. This study aims to investigate the initial efficacy and safety of obrutinib combined with R2 regimen in the treatment of relapsed or refractory CD20+B cell lymphoma

Conditions

Interventions

DRUG

Orelabrutinib tablet

Subjects received orelabrutinib150mg orally once daily for a 28-day cycle. Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up

DRUG

Lenalidomide

Lenalidomide 25mg once daily for 21 days and rituximab 375mg/m2 for 7 days Throughout the study period, all subjects continued treatment until one of the following conditions occurred: disease progression, intolerable toxicity, death, withdrawal of informed consent, or loss of follow-up

Sponsors & Collaborators

  • Puyang Oilfield General Hospital

    lead OTHER

Principal Investigators

  • Xuejun Guo, PHD · Puyang Oilfield General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2022-09-30
Completion
2023-09-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05014100 on ClinicalTrials.gov